Sensorion completed its Initial Public Offering on the Alternext market in Paris in April 2015. The company successfully raised €8.2 million (4.54 euros per share).
The biotech is specialized in the development of small molecule candidates for inner ear disorders (vestibular and/or cochlear disorders). ITI invested in the company in 2009.
Laurent Nguyen, CEO of Sensorion, comments: “On behalf of the entire company, I would like to thank all of our shareholders, both historical and new, who have chosen to support our innovative project to become a major player in the medical treatment of severe inner ear disorders. Sensorion’s Initial Public Offering on the Alternext market in Paris represents a key milestone that will enable us to accelerate our development and enhance our visibility on the pharmaceutical market.”